Health Topics — Stress & Anxiety
When Stress Becomes Something the Body Carries
For the person whose stress has stopped being a response to things and started being a condition of life — what the research names this, and what it does to the body over time.
There is a kind of tiredness that sleep doesn't fix. A heaviness that isn't sadness exactly but sits in the body the way sadness does. A sense that you have been managing for so long that managing has become the only register you know.
This is what happens when stress stops being a series of events and starts being the body's background condition. The research has a name for it. Understanding that it is a real and documented physiological state — not a personal failing, not a matter of resilience — is the first useful thing.
Stress is designed to be temporary. The body responds to a threat — cortisol rises, the nervous system mobilizes, resources are redirected — and then, when the threat passes, the body recovers. Heart rate slows. Cortisol drops. The muscles release. The systems that were deprioritized during the stress response come back online. This recovery is not a luxury. It is as much a part of the stress system as the response itself.
What happens when recovery is repeatedly incomplete — when the next stressor arrives before the body has fully returned to baseline, when the stress is chronic and the recovery never quite lands — is that the body begins to carry the accumulated cost of that unresolved activation. Researchers call this allostatic load: the measurable biological burden of sustained adaptation to stress that never fully resolves.
Allostatic load is not a metaphor. It is measurable in cortisol patterns, in inflammatory markers, in cardiovascular parameters, in immune function. It accumulates over months and years. And unlike acute stress, which resolves when the stressor passes, allostatic load persists because it represents a state the body has settled into — a recalibration of what normal looks like, at a level of activation that is higher than the body was designed to sustain.
What this does to the endocannabinoid system
The endocannabinoid system is directly involved in stress termination — the process by which the stress response ends and recovery begins. CB1 receptors in the hypothalamus and prefrontal cortex play a documented role in turning off the HPA axis after a stress event, preventing cortisol from remaining elevated longer than it needs to. Anandamide — the body's primary endocannabinoid — participates in this shutoff mechanism.
Under chronic stress, endocannabinoid tone is depleted. The enzymes that break down endocannabinoids become more active. CB1 receptor sensitivity is reduced. In plain terms: the body's own system for ending the stress response becomes less effective precisely when it is most needed. Cortisol remains elevated longer. The recovery that should follow each stress event becomes more incomplete. The allostatic load deepens.
This is a compounding pattern. Chronic stress depletes the endocannabinoid system, the depleted endocannabinoid system is less able to terminate stress responses, less effective termination means more cortisol accumulation, more cortisol further depletes endocannabinoid tone. The body settles into an activation baseline that is increasingly difficult to move from through ordinary means — which is why adequate sleep, exercise, and reduced stress load, while necessary, are sometimes not sufficient to restore a baseline that has shifted significantly.
What the research on CBG and CBD has examined
The 2024 Cuttler randomized controlled trial found that a single 20mg oral CBG dose produced statistically significant reductions in self-reported anxiety and stress compared to placebo in healthy adults. This is the most direct human evidence available for CBG's acute effects on the stress experience. It establishes a meaningful signal. It does not address what repeated dosing over time does to the allostatic load pattern — that research does not yet exist.
CBG's mechanistic relevance to accumulated stress is through two pathways. First, its alpha-2 adrenoceptor activity — reducing the norepinephrine signal that underlies sustained arousal. Second, its CB1 receptor activity — potentially supporting the endocannabinoid signaling that participates in HPA axis shutoff. Neither pathway has been studied specifically in a chronically stressed population.
CBD's FAAH inhibition mechanism — slowing the breakdown of anandamide — is relevant to the depletion pattern that accumulates under chronic stress. Supporting anandamide availability doesn't restore what chronic stress has depleted in a single dose. But consistent support for that system over time is biologically aligned with how endocannabinoid tone is maintained rather than simply triggered.
On the research limits here
No human trial has studied CBG or CBD specifically in a population carrying high allostatic load or chronic stress burden. The mechanisms described are documented and relevant. The clinical evidence specifically in this context does not yet exist.
The allostatic load pattern described here is a serious physiological state with documented health consequences. Anyone in this pattern benefits from clinical assessment as well as attention to the underlying stress biology.
What this means in practice
The tiredness that sleep doesn't fix, the heaviness that doesn't lift when the immediate stressors ease — these are not character failures. They are the documented biology of a system that has been absorbing more than it can fully process, for long enough that the baseline has shifted. Understanding that changes what you look for.
We can't tell you that a CBG or CBD preparation will reverse accumulated allostatic load. What we can say is that the endocannabinoid system is specifically implicated in the stress termination failure that allows allostatic load to accumulate — and that the mechanisms through which CBG and CBD interact with that system are documented and relevant. Consistent support for the endocannabinoid system over time is more aligned with how regulatory capacity is restored than any acute intervention would be.
Future articles in this pillar examine what happens to cortisol under chronic stress, how the HPA axis dysregulates over time, and what the research shows about the endocannabinoid system's role in stress recovery specifically. The research section is the place to start if you want the fuller picture now.
Stress that has become something the body carries is not weakness — it is physiology. The endocannabinoid system is at the center of the recovery mechanism that chronic stress depletes, and the research on CBG and CBD connects to that mechanism in documented ways. The clinical evidence in this specific population is still developing. What exists is worth understanding honestly, and that is what this archive is for.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.